{"id":"a-c-vaccine","safety":{"commonSideEffects":[{"rate":"10-30","effect":"Local injection site reactions (pain, erythema, swelling)"},{"rate":"5-15","effect":"Fever"},{"rate":"5-10","effect":"Headache"},{"rate":"5-10","effect":"Myalgia"}]},"_chembl":{"chemblId":"CHEMBL2109142","moleculeType":"Vaccine component"},"_dailymed":{"setId":"fd5652b6-5ae4-437e-a456-47deaf500794","title":"PENBRAYA (MENINGOCOCCAL GROUPS A, B, C, W, AND Y VACCINE) KIT [PFIZER LABORATORIES DIV PFIZER INC]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine contains polysaccharide antigens from meningococcal serogroups A and C, which trigger both humoral and cellular immune responses. These responses generate protective antibodies that bind to the bacterial capsule, preventing infection and disease caused by these two major meningococcal serogroups.","oneSentence":"A+C Vaccine is a combined meningococcal vaccine that stimulates the immune system to produce antibodies against Neisseria meningitidis serogroups A and C.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:58:25.458Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of meningococcal disease caused by Neisseria meningitidis serogroups A and C"}]},"trialDetails":[{"nctId":"NCT02772003","phase":"PHASE1","title":"DNA Vaccine Therapy in Treating Patients With Chronic Hepatitis C Virus Infection","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2016-06-06","conditions":"Chronic Hepatitis, Hepatitis C Infection, Hepatocellular Carcinoma","enrollment":33},{"nctId":"NCT03017820","phase":"PHASE1","title":"A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2017-04-04","conditions":"B-Cell Non-Hodgkin Lymphoma, Histiocytic and Dendritic Cell Neoplasm, Myelodysplastic Syndrome","enrollment":127},{"nctId":"NCT07215858","phase":"PHASE2","title":"BPL-1357 Against H1N1 Influenza Virus Challenge","status":"NOT_YET_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2026-04-01","conditions":"Influenza, Human","enrollment":129},{"nctId":"NCT03568058","phase":"PHASE1","title":"Personalized Immunotherapy in Adults With Advanced Cancers Immunotherapy in Adults With Advanced Cancers","status":"COMPLETED","sponsor":"Aaron Miller","startDate":"2018-07-26","conditions":"Advanced Cancer","enrollment":25},{"nctId":"NCT05992935","phase":"PHASE1, PHASE2","title":"Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age","status":"RECRUITING","sponsor":"ModernaTX, Inc.","startDate":"2023-08-25","conditions":"Norovirus Acute Gastroenteritis","enrollment":1405},{"nctId":"NCT07431853","phase":"PHASE2","title":"A Study to Learn About mRNA Vaccines Against Influenza in Adults","status":"RECRUITING","sponsor":"Pfizer","startDate":"2026-02-23","conditions":"Healthy Adults","enrollment":770},{"nctId":"NCT00338377","phase":"PHASE2","title":"Lymphodepletion Plus Adoptive Cell Transfer With or Without Dendritic Cell Immunization in Patients With Metastatic Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2006-02-01","conditions":"Melanoma","enrollment":1230},{"nctId":"NCT06738355","phase":"NA","title":"PREVENT Pilot HPV - Related Cancers Trial","status":"COMPLETED","sponsor":"University of Utah","startDate":"2025-05-20","conditions":"HPV Vaccination, Uptake Vaccination, Series Completion","enrollment":335},{"nctId":"NCT06077656","phase":"PHASE2","title":"Dose-Ranging Study to Evaluate a 25-Valent Pneumococcal Conjugate Vaccine","status":"COMPLETED","sponsor":"Inventprise Inc.","startDate":"2023-10-25","conditions":"Pneumococcal Vaccines","enrollment":220},{"nctId":"NCT04943848","phase":"PHASE1","title":"rHSC-DIPGVax Plus Checkpoint Blockade for the Treatment of Newly Diagnosed DIPG and DMG","status":"RECRUITING","sponsor":"Ann & Robert H Lurie Children's Hospital of Chicago","startDate":"2022-01-10","conditions":"Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant","enrollment":36},{"nctId":"NCT05846516","phase":"PHASE1","title":"A Study to Test KISIMA-02 Vaccine-based Immunotherapy and Ezabenlimab in People With Pancreatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Boehringer Ingelheim","startDate":"2023-05-11","conditions":"Pancreatic Ductal Adenocarcinoma","enrollment":58},{"nctId":"NCT05098210","phase":"PHASE1","title":"Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2022-06-09","conditions":"Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Locally Advanced Cutaneous Melanoma","enrollment":25},{"nctId":"NCT07183371","phase":"PHASE2","title":"A Study to Assess the Experimental Malaria Vaccines R78C and RH5.1 With Matrix-M in Combination With R21/Matrix-M","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Oxford","startDate":"2025-12-15","conditions":"Malaria,Falciparum","enrollment":360},{"nctId":"NCT06011772","phase":"EARLY_PHASE1","title":"EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Roswell Park Cancer Institute","startDate":"2023-12-18","conditions":"Colo-rectal Cancer","enrollment":2},{"nctId":"NCT06958198","phase":"PHASE1","title":"A Study to Assess the Experimental Malaria Vaccines R78C and RH5.1 Combined With R21/Matrix-M (a \"Multi-stage\" Malaria Vaccine)","status":"RECRUITING","sponsor":"University of Oxford","startDate":"2025-09-15","conditions":"Malaria,Falciparum","enrollment":56},{"nctId":"NCT07460154","phase":"NA","title":"Structured Review: To Optimise Management and Prevent Harm in COPD","status":"NOT_YET_RECRUITING","sponsor":"Northumbria Healthcare NHS Foundation Trust","startDate":"2026-03-01","conditions":"COPD","enrollment":96},{"nctId":"NCT07217145","phase":"NA","title":"PREVENT HPV -Related Cancers Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Utah","startDate":"2025-10-09","conditions":"HPV Vaccination, Uptake Vaccination, Series Completion","enrollment":1455},{"nctId":"NCT02285816","phase":"PHASE1, PHASE2","title":"MG1 Maraba/MAGE-A3, With and Without Adenovirus Vaccine With Transgenic MAGE-A3 Insertion in Incurable MAGE-A3-Expressing Solid Tumours","status":"ACTIVE_NOT_RECRUITING","sponsor":"Canadian Cancer Trials Group","startDate":"2015-01-22","conditions":"Advanced/Metastatic Solid Tumours","enrollment":56},{"nctId":"NCT07455318","phase":"PHASE3","title":"Boostability Assessment of Three Rabies Pre-Exposure Regimens in Healthy Volunteers 5 Years Following Priming.","status":"NOT_YET_RECRUITING","sponsor":"Institute of Tropical Medicine, Belgium","startDate":"2026-05-15","conditions":"Rabies (Healthy Volunteers)","enrollment":561},{"nctId":"NCT05935176","phase":"PHASE4","title":"Phase IV Clinical Study of Immunogenicity of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector)","status":"ACTIVE_NOT_RECRUITING","sponsor":"CanSino Biologics Inc.","startDate":"2023-09-20","conditions":"Epidemic Meningitis","enrollment":660},{"nctId":"NCT07443709","phase":"PHASE2","title":"Zoster Vaccine to Enhance Protection Against Zoster in Solid-organ Transplantation","status":"NOT_YET_RECRUITING","sponsor":"Oriol Manuel","startDate":"2026-04","conditions":"Zoster; Herpes","enrollment":75},{"nctId":"NCT04006457","phase":"PHASE3","title":"Long-Term PF-06651600 for the Treatment of Alopecia Areata","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2019-07-18","conditions":"Alopecia Areata","enrollment":1052},{"nctId":"NCT05415267","phase":"PHASE3","title":"Immunosuppression and COVID-19 Boosters","status":"RECRUITING","sponsor":"Kirby Institute","startDate":"2023-07-21","conditions":"COVID-19","enrollment":320},{"nctId":"NCT06505993","phase":"NA","title":"Addressing COVID-19 Vaccine Hesitancy With Muliti-Level Interventions in Appalachia","status":"SUSPENDED","sponsor":"Marc Kiviniemi","startDate":"2026-09","conditions":"COVID-19, Vaccine Hesitancy","enrollment":2250},{"nctId":"NCT03866187","phase":"PHASE1, PHASE2","title":"Safety, Efficacy, Immunogenicity Study of GSK Biologicals' HBV Viral Vector and Adjuvanted Proteins Vaccine (GSK3528869A) in Adult Patients With Chronic Hepatitis B Infection","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2019-03-28","conditions":"Hepatitis B, Chronic","enrollment":236},{"nctId":"NCT06342908","phase":"PHASE1","title":"A Vaccine (Neoantigen-Targeted ppDC) for the Treatment of H3 G34-mutant Diffuse Hemispheric Glioma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2024-06-14","conditions":"Diffuse Hemispheric Glioma, H3 G34-Mutant","enrollment":6},{"nctId":"NCT04041310","phase":"PHASE1, PHASE2","title":"Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Nouscom SRL","startDate":"2019-10-21","conditions":"Solid Tumor, Adult","enrollment":115},{"nctId":"NCT07400003","phase":"PHASE1, PHASE2","title":"Study to Evaluate the Safety and Immunogenicity of a Lyophilized Herpes Zoster Virus mRNA Vaccine","status":"RECRUITING","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2026-01-06","conditions":"Herpes Zoster, mRNA Vaccine","enrollment":519},{"nctId":"NCT05762393","phase":"PHASE1","title":"A Study to Evaluate the Safety, Tolerability, and Immunogenicity of the Sm-p80 + GLA-SE (SchistoShield®) Candidate Vaccine in Healthy Adults in Burkina Faso and Madagascar","status":"COMPLETED","sponsor":"International Vaccine Institute","startDate":"2023-11-17","conditions":"Schistosomiasis","enrollment":120},{"nctId":"NCT06143046","phase":"PHASE2","title":"A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus in Pregnant Women and in Infants Born to Vaccinated Mothers","status":"ACTIVE_NOT_RECRUITING","sponsor":"ModernaTX, Inc.","startDate":"2023-11-15","conditions":"Respiratory Syncytial Virus","enrollment":360},{"nctId":"NCT05500417","phase":"PHASE1","title":"Safety and Immunogenicity of CJCV2 With and Without ALFQ","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2022-09-13","conditions":"Campylobacter Infection","enrollment":59},{"nctId":"NCT06663436","phase":"PHASE2","title":"A Study on the Immune Response and Safety of a Multicomponent Shigella Vaccine in Preventing Shigellosis in Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2024-11-13","conditions":"Diarrhoea","enrollment":200},{"nctId":"NCT04607408","phase":"PHASE1","title":"Evaluating Safety and Immune Response to the HIV-1 CH505 Transmitted/Founder gp120 Adjuvanted With GLA-SE in Healthy, HIV-exposed Uninfected Infants","status":"COMPLETED","sponsor":"HIV Vaccine Trials Network","startDate":"2020-11-10","conditions":"HIV Infections","enrollment":38},{"nctId":"NCT02600949","phase":"PHASE1","title":"Personalized Peptide Vaccine in Treating Patients With Advanced Pancreatic Cancer or Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2016-05-11","conditions":"Metastatic Colorectal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma, Stage IV Colorectal Cancer AJCC v7","enrollment":117},{"nctId":"NCT05751798","phase":"PHASE1, PHASE2","title":"Dose-finding and Dose Expansion Study of OSE-279 in Subjects With Advanced Solid Tumors or Lymphomas","status":"RECRUITING","sponsor":"OSE Immunotherapeutics","startDate":"2022-12-20","conditions":"Solid Advanced Tumor, Lymphoma, NSCLC (Non-small Cell Lung Cancer)","enrollment":41},{"nctId":"NCT05805826","phase":"PHASE1, PHASE2","title":"To Understand the Safety and Effects of a C. Difficile Vaccine With New Adds-Ons That Will Be Given to Healthy Adults","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2023-03-23","conditions":"Clostridoides Difficile Associated Disease","enrollment":936},{"nctId":"NCT06821061","phase":"PHASE1, PHASE2","title":"A Study to Learn About How the Flu and COVID-19 Vaccines Act in Healthy People","status":"COMPLETED","sponsor":"BioNTech SE","startDate":"2025-02-10","conditions":"Influenza, COVID-19 (Coronavirus Disease 2019)","enrollment":2650},{"nctId":"NCT07054931","phase":"PHASE2","title":"Combination Vaccination and Broadly Neutralising Antibody Therapy in HIV","status":"RECRUITING","sponsor":"University of Oxford","startDate":"2025-09-05","conditions":"HIV","enrollment":48},{"nctId":"NCT07286370","phase":"PHASE2","title":"A Study to Evaluate Safety, Reactogenicity, and Immune Response of GVGH iNTS-TCV Vaccine Against Invasive Nontyphoidal Salmonella Disease and Typhoid Fever in Infants","status":"NOT_YET_RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2026-02-16","conditions":"Salmonella Infections","enrollment":537},{"nctId":"NCT07122986","phase":"PHASE1","title":"A Study to Learn About a Vaccine Against E Coli in Healthy Adults","status":"RECRUITING","sponsor":"Pfizer","startDate":"2025-08-11","conditions":"Healthy Participants","enrollment":310},{"nctId":"NCT05794230","phase":"PHASE3","title":"Study of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Given With Routine Pediatric Vaccines in Healthy Infants and Toddlers in India and the Republic of South Africa","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2023-03-27","conditions":"Meningococcal Immunisation, Healthy Volunteers","enrollment":1528},{"nctId":"NCT07354659","phase":"PHASE2","title":"Immunogenicity and Safety of SYS6017 in the Participants Aged 40 Years and Above","status":"NOT_YET_RECRUITING","sponsor":"CSPC Megalith Biopharmaceutical Co.,Ltd.","startDate":"2026-01-10","conditions":"Herpes Zoster","enrollment":800},{"nctId":"NCT04869592","phase":"PHASE1, PHASE2","title":"A Clinical Trial to Evaluate the Recombinant SARS-CoV-2 Vaccine (CHO Cell) for COVID-19","status":"COMPLETED","sponsor":"National Vaccine and Serum Institute, China","startDate":"2021-04-25","conditions":"COVID-19","enrollment":3100},{"nctId":"NCT07347210","phase":"PHASE2","title":"Evaluation of UCPVax Vaccine +/- Pembrolizumab Combined With Standard Treatment as Adjuvant Therapy in Patients With Unmethylated MGMT Glioblastoma","status":"NOT_YET_RECRUITING","sponsor":"Centre Hospitalier Universitaire de Besancon","startDate":"2026-01","conditions":"Primary Glioblastoma","enrollment":98},{"nctId":"NCT06560151","phase":"PHASE2","title":"Assess Safety and Immunogenicity of A/H5 Inactivated Monovalent Influenza Vaccines at Different Antigen Dose Levels Adjuvanted With AS03 or MF59","status":"COMPLETED","sponsor":"Biomedical Advanced Research and Development Authority","startDate":"2024-08-21","conditions":"Influenza","enrollment":1380},{"nctId":"NCT05417165","phase":"PHASE2","title":"Anti-pneumococcal Vaccine Strategy in Patients With Chronic Lymphocytic Leukemia","status":"RECRUITING","sponsor":"Seema Bhat","startDate":"2023-09-29","conditions":"Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma","enrollment":80},{"nctId":"NCT05968989","phase":"PHASE1","title":"Trial to Evaluate the Safety, Tolerability, and Immunogenicity of a Mosaic Hexavalent Influenza Vaccine VRC-FLUMOS0116-00-VP (FluMos-v2) in Healthy Adults","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2023-08-09","conditions":"Influenza","enrollment":30},{"nctId":"NCT07320716","phase":"PHASE2","title":"Long-Term Immunogenicity of the altSonflex1-2-3 Shigella Vaccine in African Children","status":"NOT_YET_RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2026-01-02","conditions":"Diarrhoea","enrollment":528},{"nctId":"NCT05658523","phase":"PHASE3","title":"COVID-19 Booster Study in Healthy Adults in Australia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Murdoch Childrens Research Institute","startDate":"2023-02-28","conditions":"COVID-19","enrollment":496},{"nctId":"NCT05172011","phase":"","title":"Understanding the Long-term Impact of COVID on Children and Families","status":"ACTIVE_NOT_RECRUITING","sponsor":"NYU Langone Health","startDate":"2022-03-01","conditions":"SARS-CoV-2 Infection","enrollment":15028},{"nctId":"NCT05330975","phase":"PHASE3","title":"A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥50 Years of Age","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2022-04-01","conditions":"Respiratory Syncytial Virus","enrollment":3317},{"nctId":"NCT06834100","phase":"PHASE3","title":"Assessment of Immunogenicity, Reactogenicity and Safety of the Drug GNG-DE in Comparison With the Reference Drug","status":"RECRUITING","sponsor":"NPO Petrovax","startDate":"2025-02-12","conditions":"Infections, Meningococcal","enrollment":240},{"nctId":"NCT05182125","phase":"PHASE1","title":"Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of HIV-1 Chimp Adenovirus Vaccines Expressing Clade C gp140 & CH505TF gp120 Protein Boost in HIV-uninfected Adult.","status":"COMPLETED","sponsor":"HIV Vaccine Trials Network","startDate":"2021-11-25","conditions":"HIV Infections","enrollment":34},{"nctId":"NCT05827926","phase":"PHASE1, PHASE2","title":"A Study of mRNA-based Influenza and SARS-CoV-2 (COVID-19) Multi-component Vaccines in Healthy Adults","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2023-04-14","conditions":"SARS-CoV-2, Influenza","enrollment":1758},{"nctId":"NCT06822907","phase":"PHASE4","title":"Immunogenicity and Safety PCV-20 of the Vaccine Administered During an Acute Febrile Illness in Adults","status":"NOT_YET_RECRUITING","sponsor":"Centre Hospitalier Universitaire de Saint Etienne","startDate":"2026-01","conditions":"Acute Febrile Illness, Pneumococcal Infections","enrollment":1052},{"nctId":"NCT07197762","phase":"PHASE4","title":"MenB-FHbp or MenACWY-TT/MenB-FHbp Vaccine in MenB-4C Primed Young Adults","status":"RECRUITING","sponsor":"Emory University","startDate":"2025-11-04","conditions":"Neisseria Meningitidis","enrollment":125},{"nctId":"NCT05208710","phase":"EARLY_PHASE1","title":"PANHPVAX, Study of a New HPV Vaccine in Healthy Volunteers","status":"RECRUITING","sponsor":"German Cancer Research Center","startDate":"2022-11-07","conditions":"HPV","enrollment":45},{"nctId":"NCT06079606","phase":"","title":"The Effects of Antibiotic Exposure in Early Infancy on Vaccine Responses","status":"ACTIVE_NOT_RECRUITING","sponsor":"Landspitali University Hospital","startDate":"2022-09-10","conditions":"Immune Responses, Antibiotic Treatment","enrollment":200},{"nctId":"NCT07289503","phase":"PHASE1","title":"Phase I Clinical Trial of Lyophilized Respiratory Syncytial Virus mRNA Vaccine in Adults Aged 18 Years or Above","status":"ACTIVE_NOT_RECRUITING","sponsor":"Suzhou Abogen Biosciences Co., Ltd.","startDate":"2025-05-27","conditions":"Respiratory Syncytial Virus","enrollment":96},{"nctId":"NCT04445064","phase":"PHASE2","title":"Activity and Safety of Peptide-based Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck.","status":"TERMINATED","sponsor":"Cliniques universitaires Saint-Luc- Université Catholique de Louvain","startDate":"2020-08-14","conditions":"Oropharynx Squamous Cell Carcinoma, Larynx Squamous Cell Carcinoma, Hypopharynx Squamous Cell Carcinoma","enrollment":17},{"nctId":"NCT07285265","phase":"PHASE1","title":"Phase I Clinical Trial of Lyophilized Herpes Zoster mRNA Vaccine in Adults Aged 40 Years or Above","status":"ACTIVE_NOT_RECRUITING","sponsor":"Suzhou Abogen Biosciences Co., Ltd.","startDate":"2025-05-27","conditions":"Varicella-zoster Virus","enrollment":180},{"nctId":"NCT05575492","phase":"PHASE1, PHASE2","title":"A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age","status":"ACTIVE_NOT_RECRUITING","sponsor":"ModernaTX, Inc.","startDate":"2022-11-07","conditions":"Cytomegalovirus","enrollment":873},{"nctId":"NCT06670755","phase":"NA","title":"ID93/GLA-SE Vaccination + BCG Challenge","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Oxford","startDate":"2024-12-18","conditions":"Tuberculosis","enrollment":48},{"nctId":"NCT06686654","phase":"PHASE1, PHASE2","title":"Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2024-11-11","conditions":"Human Metapneumovirus Immunization, Respiratory Syncytial Virus Immunization","enrollment":1530},{"nctId":"NCT07267585","phase":"","title":"Unravelling the Measles Paradox (MISIA)","status":"RECRUITING","sponsor":"Erasmus Medical Center","startDate":"2025-07-03","conditions":"MEASLES DISEASE","enrollment":300},{"nctId":"NCT05073003","phase":"PHASE1","title":"A Study on the Safety and Immune Responses to the GVGH altSonflex1-2-3 Vaccine Against Shigellosis in Adults, Children, and Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2021-10-06","conditions":"Diarrhoea","enrollment":551},{"nctId":"NCT06178991","phase":"PHASE3","title":"A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Combined Modified RNA Vaccine Candidate Against COVID-19 and Influenza.","status":"COMPLETED","sponsor":"BioNTech SE","startDate":"2023-12-20","conditions":"Influenza, COVID-19","enrollment":8795},{"nctId":"NCT02451982","phase":"PHASE2","title":"Platform Study of Neoadjuvant and Adjuvant Immunotherapy for Patients With Resectable Adenocarcinoma of the Pancreas","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2016-03-28","conditions":"Pancreatic Cancer","enrollment":76},{"nctId":"NCT04248569","phase":"PHASE1","title":"DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Fibrolamellar Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2020-04-20","conditions":"Fibrolamellar Hepatocellular Carcinoma (FLC)","enrollment":56},{"nctId":"NCT04843111","phase":"","title":"Observational, Passive Surveillance Program to Collect Information on Women and Their Offspring Exposed to MenQuadfi® During Pregnancy, in United States (US)","status":"RECRUITING","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2021-03-05","conditions":"Meningococcal Infection","enrollment":50},{"nctId":"NCT07204457","phase":"PHASE2, PHASE3","title":"Immunogenicity and Safety of Meningococcal Conjugate Vaccine (EG-MCV4) in Healthy Adults Aged 19 to 55 Years Old","status":"RECRUITING","sponsor":"EyeGene Inc.","startDate":"2025-10-15","conditions":"Meningococcal Infections","enrollment":1123},{"nctId":"NCT05480800","phase":"PHASE1, PHASE2","title":"A Study to Evaluate Safety, Reactogenicity, and Immune Response of GVGH iNTS-TCV Vaccine Against Invasive Nontyphoidal Salmonella and Typhoid Fever","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2022-09-13","conditions":"Salmonella Infections","enrollment":155},{"nctId":"NCT05606965","phase":"PHASE2","title":"A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1010 in Healthy Adults","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2022-11-02","conditions":"Influenza","enrollment":172},{"nctId":"NCT05743881","phase":"PHASE1","title":"A Safety, Tolerability, and Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months","status":"ACTIVE_NOT_RECRUITING","sponsor":"ModernaTX, Inc.","startDate":"2023-02-15","conditions":"Respiratory Syncytial Virus, Human Metapneumovirus","enrollment":186},{"nctId":"NCT06798454","phase":"PHASE1","title":"Single Ascending Dose Study to Evaluate Safety Tolerability, Pharmacokinetics, and Pharmacodynamics of PVT201 in Healthy Subjects and Patients (PBC/PSC)","status":"COMPLETED","sponsor":"Parvus Therapeutics, Inc.","startDate":"2024-10-15","conditions":"Primary Biliary Cholangitis (PBC)","enrollment":24},{"nctId":"NCT06015841","phase":"PHASE2","title":"A Study to Evaluate the Effects of ACI-7104.056 in Patients With Early Stages of Parkinson's Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"AC Immune SA","startDate":"2023-07-24","conditions":"Parkinson Disease, Parkinson Disease 6, Early-Onset","enrollment":150},{"nctId":"NCT04166656","phase":"PHASE3","title":"Research Trial Assessing the Immunogenicity and Safety of Three Meningococcal B Vaccine Strategies Among Patients With Asplenia.","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2022-09-15","conditions":"Splenectomy","enrollment":84},{"nctId":"NCT03069703","phase":"PHASE2","title":"Innovative Anti-pneumococcal Vaccine Strategies in Patients With ANCA-associated Vasculitis Receiving Rituximab Therapy","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2018-02-05","conditions":"Invasive Pneumococcal Infection","enrollment":96},{"nctId":"NCT06246851","phase":"NA","title":"BCG Revaccination Study in Diabetic and Non-Diabetic Adults","status":"ENROLLING_BY_INVITATION","sponsor":"University of Oxford","startDate":"2024-04-03","conditions":"Tuberculosis","enrollment":36},{"nctId":"NCT07147400","phase":"PHASE2","title":"Pfs230D1 + R21 in Matrix-M1 in African School Children and Adults","status":"RECRUITING","sponsor":"Serum Institute of India Pvt. Ltd.","startDate":"2025-08-22","conditions":"Prevention of Malaria Transmission and Clinical Malaria","enrollment":1200},{"nctId":"NCT02955290","phase":"PHASE1, PHASE2","title":"CIMAvax Vaccine, Nivolumab, and Pembrolizumab in Treating Patients With Advanced Non-small Cell Lung Cancer or Squamous Head and Neck Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Roswell Park Cancer Institute","startDate":"2016-12-22","conditions":"Advanced Head and Neck Squamous Cell Carcinoma, Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma","enrollment":51},{"nctId":"NCT04329065","phase":"PHASE2","title":"Concurrent WOKVAC Vaccination, Chemotherapy, and HER2-Targeted Monoclonal Antibody Therapy Before Surgery for the Treatment of Patients With Breast Cancer","status":"RECRUITING","sponsor":"University of Washington","startDate":"2022-04-20","conditions":"Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8","enrollment":25},{"nctId":"NCT03910972","phase":"PHASE1, PHASE2","title":"Sm-TSP-2 Schistosomiasis Vaccine in Healthy Ugandan Adults","status":"COMPLETED","sponsor":"Baylor College of Medicine","startDate":"2019-10-07","conditions":"Schistosomiasis, Schistosoma Mansoni","enrollment":290},{"nctId":"NCT05479370","phase":"PHASE3","title":"Immunogenicity Trial of 3 Influenza Vaccines","status":"COMPLETED","sponsor":"Tan Tock Seng Hospital","startDate":"2022-09-29","conditions":"Influenza Vaccination","enrollment":366},{"nctId":"NCT03758625","phase":"PHASE1","title":"Comparison of Dendritic Cell-Based Therapeutic Vaccine Strategies for HIV Functional Cure","status":"COMPLETED","sponsor":"Sharon Riddler","startDate":"2019-01-02","conditions":"HIV Infections","enrollment":40},{"nctId":"NCT06864143","phase":"PHASE2","title":"A Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (Influenza and COVID-19) Vaccine in Adults ≥18 to <65 Years of Age","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2025-03-07","conditions":"Influenza, SARS-CoV-2","enrollment":1320},{"nctId":"NCT05432583","phase":"PHASE1","title":"A Clinical Trial in Healthy Volunteers and Volunteers With Recurrent Genital Herpes to Study the Safety, Tolerability, and Immune Responses After Vaccination With an Investigational Vaccine Designed to Prevent Genital Herpes Lesions","status":"ACTIVE_NOT_RECRUITING","sponsor":"BioNTech SE","startDate":"2022-12-08","conditions":"Genital Herpes Simplex Type 2","enrollment":318},{"nctId":"NCT06508320","phase":"PHASE2","title":"A Clinical Study to Investigate the Safety and Immunogenicity in Relation to Product Attributes of mRNA-1083 (Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2] and Influenza Vaccine)","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2024-07-15","conditions":"Influenza, SARS-CoV-2","enrollment":932},{"nctId":"NCT04825223","phase":"PHASE1","title":"Study of a Novel Multicomponent Meningococcal Group B Vaccine When Given Alone or With Other Licensed Vaccines in Adults, Adolescents, Toddlers and Infants","status":"TERMINATED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2021-03-29","conditions":"Meningococcal Immunisation, Healthy Volunteers","enrollment":576},{"nctId":"NCT07205796","phase":"PHASE2","title":"A Phase 2 Study to Describe the Safety, Reactogenicity, and Immunogenicity of Herpes Zoster IN001 mRNA Vaccine (IN001) in Healthy Participants","status":"NOT_YET_RECRUITING","sponsor":"Shenzhen Shenxin Biotechnology Co., Ltd","startDate":"2026-05-01","conditions":"Herpes Zoster","enrollment":480},{"nctId":"NCT00694655","phase":"PHASE4","title":"Human Immune Responses to Yellow Fever Vaccination","status":"COMPLETED","sponsor":"Emory University","startDate":"2008-05","conditions":"Yellow Fever","enrollment":239},{"nctId":"NCT01861938","phase":"PHASE2, PHASE3","title":"Modified Melanoma Vaccine for High Risk or Low Residual Disease Patients","status":"WITHDRAWN","sponsor":"Hadassah Medical Organization","startDate":"2017-03","conditions":"High Risk HLA-A2+ Melanoma, Metastatic Disease","enrollment":""},{"nctId":"NCT05295290","phase":"PHASE4","title":"A Study to Learn About The COVID-19 (Study) Vaccine (Called COMIRNATY) in People That Are Less Than 21 Years Old.","status":"RECRUITING","sponsor":"Pfizer","startDate":"2022-11-21","conditions":"Myocarditis","enrollment":300},{"nctId":"NCT05304351","phase":"PHASE2","title":"Safety and Immunogenicity of CRV-101 Vaccine for the Prevention of Herpes Zoster in Adults Aged 50 Years and Older","status":"ACTIVE_NOT_RECRUITING","sponsor":"Curevo Inc","startDate":"2022-02-02","conditions":"Herpes Zoster, Shingles","enrollment":1516},{"nctId":"NCT04705116","phase":"","title":"COVID-19 Vaccines International Pregnancy Exposure Registry","status":"RECRUITING","sponsor":"Pregistry","startDate":"2021-06-01","conditions":"Covid19","enrollment":6000},{"nctId":"NCT03029403","phase":"PHASE2","title":"Phase 2 Study of Pembrolizumab, DPX-Survivac Vaccine and Cyclophosphamide in Advanced Ovarian, Primary Peritoneal or Fallopian Tube Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2018-02-12","conditions":"Advanced Cancer, Ovarian Cancer, Primary Peritoneal Carcinoma","enrollment":47},{"nctId":"NCT00437021","phase":"PHASE1, PHASE2","title":"MVA Post-Event: Administration Timing and Boost Study","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2007-04-16","conditions":"Smallpox","enrollment":226},{"nctId":"NCT06228586","phase":"PHASE3","title":"Study on a MenACYW Conjugate Vaccine Administered as a Single Dose in Participants Aged 12 Months and Older in Vietnam","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2024-01-18","conditions":"Meningococcal Infection, Healthy Volunteers","enrollment":447},{"nctId":"NCT07172074","phase":"NA","title":"Comparing Relative Strengths of Statistical Associations Between Psychological Traits and Vaccination-Related Outcomes I","status":"COMPLETED","sponsor":"University of Iowa","startDate":"2022-12-30","conditions":"Vaccination, Vaccination Hesitancy, Vaccination Promotion","enrollment":1786},{"nctId":"NCT04368429","phase":"PHASE3","title":"Study of a Quadrivalent Meningococcal Conjugate Vaccine as a Single Dose Compared With a Single Dose of a Meningococcal Reference Vaccine in Children, Adolescents, and Adults 2 to 55 Years of Age","status":"COMPLETED","sponsor":"Sanofi","startDate":"2020-05-22","conditions":"Meningococcal Immunisation (Healthy Volunteers)","enrollment":360}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":24,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"A+C Vaccine","genericName":"A+C Vaccine","companyName":"Jiangsu Province Centers for Disease Control and Prevention","companyId":"jiangsu-province-centers-for-disease-control-and-prevention","modality":"Biologic","firstApprovalDate":"","aiSummary":"The A+C vaccine, also known as TG4040, is being studied in clinical trials for various conditions, including Chronic Hepatitis C Infection, Influenza, and Genital Herpes. It is administered in combination with standard of care (SOC) treatments, such as pegylated interferon and ribavirin, and QIVc.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}